Brussels - 7 December 2023.

Kantify, the TechBio company pioneering AI-driven drug discovery, announces the appointment of Dr. Eckhard von Keutz, PhD, as Scientific Advisor.

Renowned as an independent professional and former Senior Vice President and Head of Translational Sciences at Bayer Pharmaceuticals, Dr. von Keutz brings a wealth of experience to Kantify.

With a distinguished career that includes leadership roles at Bayer AG, such as Senior Vice President and Global Head of Early Development, Vice President and Global Head of HealthCare Toxicology and Senior Director and Global Head of Toxicology-Pharma, his expertise encompasses the supervision of preclinical drug discovery and early development projects, management of interdisciplinary teams, and innovation in preclinical drug discovery and implementation of New Approach Methodologies.

Dr. von Keutz's appointment marks a significant milestone for Kantify.

Kantify CEO Segolene Martin declares:

We welcome Dr von Keutz’ invaluable insights and anticipate that his expertise will play a pivotal role in shaping the future of next generation drug discovery.

In welcoming Dr. von Keutz, Kantify reinforces its dedication to meaningful and complementary collaborations in the biopharma sector. The TechBio firm is committed to making a positive and lasting impact on medicine by harnessing the power of AI to accelerate drug discovery, develop novel therapies, and enhance patient outcomes.

About Kantify

Kantify is a Belgian TechBio company at the forefront of AI-driven biotechnology innovation, with the mission to improve human health with artificial intelligence. The company has developed Sapian, an AI technology that accelerates drug discovery at scale by discovering novel therapies for untreated diseases. With a proven track record of cutting-edge research and practical applications, Kantify specializes in the discovery of small molecules and protein degraders utilizing artificial intelligence.